ESG Report 2022

Normalizing Healthiness Improving Medical Accessibi l ity Our Focuses Innovation and R&D Supporting the Medical Industry Our Actions Strengthen Research and Innovation Increase Pharmaceutical Accessibility Improve Pharmaceutical Affordability Improve Healthcare Standards Our Achievements Annual R&D investment 5.94 RMB million 62 Products Included in the Naional Medical Insurance Drug List 30 Products 11,000+ people Included in the National Essential Drug List Participate in " Double Excellence Action " 10 Environmental, Social and Governance Report 2022 The United Laboratories International Holdings Limited